SMARCA4 and lung carcinoma: The overall mutation rate for SMARCA4 in NSCLC was 9% according to our genetic analysis, with poorly differentiated NSCLC exhibiting an approximately 12% mutation rate, highlighting the importance of vigilance regarding SMARCA4 mutations in lung cancer patients [12].